Modality
Small Molecule
MOA
PD-1i
Target
EGFR
Pathway
NF-κB
IPF
Development Pipeline
Preclinical
~Oct 2023
→ ~Jan 2025
Phase 1
Apr 2025
→ Nov 2026
Phase 1Current
NCT05075441
198 pts·IPF
2025-04→2026-11·Not yet recruiting
198 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-087mo awayPh2 Data· IPF
Trial Timeline
Q2Q3Q42026Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2026-11-08 · 7mo away
IPF
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05075441 | Phase 1/2 | IPF | Not yet recr... | 198 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Adagraderotide | Olema | Phase 2 | EGFR |